Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jessica Vreugdenhil"'
Autor:
Annemart Koornneef, Kanika Vanshylla, Gijs Hardenberg, Lucy Rutten, Nika M. Strokappe, Jeroen Tolboom, Jessica Vreugdenhil, Karin Feddes-de Boer, Aditya Perkasa, Sven Blokland, Judith A. Burger, Wei-Chiao Huang, Jonathan F. Lovell, Danielle van Manen, Rogier W. Sanders, Roland C. Zahn, Hanneke Schuitemaker, Johannes P. M. Langedijk, Frank Wegmann
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipi
Externí odkaz:
https://doaj.org/article/b47f9ae471c641c184638edf81cb1133
Autor:
Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, Ella van Huizen, Johan Verspuij, Ana Izquierdo Gil, Ying Choi, Chenandly Daal, Aditya Perkasa, Adriaan de Wilde, Erwin Claassen, Rineke de Jong, Katrin E. Wiese, Lisette Cornelissen, Marieke van Es, Marjolein van Heerden, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Jessica Vreugdenhil, Karin Feddes - de Boer, Leacky Muchene, Jeroen Tolboom, Liesbeth Dekking, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract Since the original outbreak of the SARS-CoV-2 virus, several rapidly spreading SARS-CoV-2 variants of concern (VOC) have emerged. Here, we show that a single dose of Ad26.COV2.S (based on the Wuhan-Hu-1 spike variant) protects against the Ga
Externí odkaz:
https://doaj.org/article/225f12fc050d4eedbec35ffc6652125e
Autor:
Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, Ying Choi, Miranda R. M. Baert, Karin Feddes-de Boer, Ana Izquierdo Gil, Marjolein van Heerden, Tim J. Dalebout, Sebenzile K. Myeni, Marjolein Kikkert, Eric J. Snijder, Leon de Waal, Koert J. Stittelaar, Jeroen T. B. M. Tolboom, Jan Serroyen, Leacky Muchene, Leslie van der Fits, Lucy Rutten, Johannes P. M. Langedijk, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human
Externí odkaz:
https://doaj.org/article/fc2cb2bea71d44b4a49590c0dc2b55f2
Autor:
Joan E. M. van der Lubbe, Jessica Vreugdenhil, Sarra Damman, Joost Vaneman, Jaco Klap, Jaap Goudsmit, Katarina Radošević, Ramon Roozendaal
Publikováno v:
Virology Journal, Vol 14, Iss 1, Pp 1-12 (2017)
Abstract Background Various studies have shown that infants under the age of 6 months are especially vulnerable for complications due to influenza. Currently there are no vaccines licensed for use in this age group. Vaccination of pregnant women duri
Externí odkaz:
https://doaj.org/article/eca3622f79424008814481b2c9992526
Autor:
Jerome Custers, Jessica Vreugdenhil, Roland Zahn, Adriaan H. de Wilde, Frank Wegmann, Babs E. Verstrepen, Ella van Huizen, Ivanela Kondova, Joan E.M. van der Lubbe, Jeroen Tolboom, Joke Drijver, Mandy Jongeneelen, Joost Vaneman, Dominika N. Czapska-Casey, Laura Solforosi, Eric J. Snijder, Willy M. J. M. Bogers, Miranda R.M. Baert, Daniel Veldman, Kinga P. Böszörményi, Hanneke Schuitemaker, Leacky Muchene, Eleni Kourkouta, Harmjan Kuipers, Ying Choi, Ernst J. Verschoor, Ana Izquierdo Gil, Marjolein van Heerden, Marieke A. Stammes, Tim J. Dalebout, Liesbeth Dekking, Petra Mooij, Krisztian Kaszas, Ramon Roozendaal, Sanne Kroos, Sebenzile K. Myeni, Jeroen Huizingh, Remko Van Der Vlugt, Boerries Brandenburg, Marjolein Kikkert, Sietske K. Rosendahl Huber, Gerrit Koopman, Dan H. Barouch
Publikováno v:
Journal of Experimental Medicine
The Journal of Experimental Medicine
Journal of Experimental Medicine, 218(7). ROCKEFELLER UNIV PRESS
The Journal of Experimental Medicine
Journal of Experimental Medicine, 218(7). ROCKEFELLER UNIV PRESS
While single-dose COVID-19 vaccines are preferred, two-dose regimens may improve efficacy. Immunogenicity of Ad26.COV2.S is improved in NHPs after a second dose, whereas both regimens protect animals against SARS-CoV-2 disease and elicit neutralizing
Autor:
Lucy Rutten, Tim J. Dalebout, Liesbeth Dekking, Dan H. Barouch, Koert J. Stittelaar, Hanneke Schuitemaker, Frank Wegmann, Marjolein van Heerden, Joan E.M. van der Lubbe, Roland Zahn, Jessica Vreugdenhil, Sebenzile K. Myeni, Johannes P. M. Langedijk, Ella van Huizen, Miranda R.M. Baert, Leacky Muchene, Jan Serroyen, Marjolein Kikkert, Jeroen Tolboom, Ana Izquierdo Gil, Ying Choi, Sietske K. Rosendahl Huber, Karin Feddes-de Boer, Aneesh Vijayan, Leon de Waal, Eric J. Snijder, Leslie van der Fits
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26) vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26.COV2.S) is immunogenic and provides protection in Syrian hamster and non-human primate S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aebc400ef746539a4e9acf90c43787e1
https://doi.org/10.1101/2021.01.08.425915
https://doi.org/10.1101/2021.01.08.425915
Autor:
Ramon Roozendaal, Joan E. M. van der Lubbe, Joost Vaneman, Katarina Radosevic, Jaap Goudsmit, Jessica Vreugdenhil, Sarra Damman, J.M. Klap
Publikováno v:
Virology Journal, Vol 14, Iss 1, Pp 1-12 (2017)
Virology Journal
Virology Journal
Background Various studies have shown that infants under the age of 6 months are especially vulnerable for complications due to influenza. Currently there are no vaccines licensed for use in this age group. Vaccination of pregnant women during the la
Autor:
Mo Weijtens, Lauren Peter, Glenda Gray, Katleen Callewaert, Erica N. Borducchi, David C. Montefiori, Thomas B. Campbell, Frank Tomaka, Kathy Mngadi, Fatima Laher, Joseph P. Nkolola, David Jetton, Jenny Hendriks, Roland Zahn, Frances Priddy, Edith Swann, Juliet Mpendo, Sorachai Nitayapan, Karin Feddes-de Boer, Wenjun Li, Stephan Bart, Erica Lazarus, Abishek Chandrashekar, Jennifer Johnson, Frank Wegmann, Steven Nijs, Lindsey R. Baden, Merlin L. Robb, Nigel Garrett, Ludo Lavreys, Galit Alter, Dan H. Barouch, Etienne Karita, Hanneke Schuitemaker, Daniel J. Stieh, Georgia D. Tomaras, Nicole Frahm, M. Juliana McElrath, Danielle van Manen, Zelda Euler, Gregg Lucksinger, Lorenz Scheppler, Hannah Kibuuka, Robert Feldman, Raphaele Roten, Maria G. Pau, Kathryn E. Stephenson, Caroline Borremans, Nelson L. Michael, Punnee Pitisuttithum, Jessica Vreugdenhil, Jeroen Tolboom, Jerald C. Sadoff, Kundai Chinyenze, Bette T. Korber, Julia Hutter
Publikováno v:
Lancet, 392(10143), 232-243. Elsevier Limited
Summary Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6169a5479eb278fd28c754f353bca4e7
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html